About Longwood Healthcare Leaders Meeting
聚会简介
瑞士生物手艺日是瑞士领先的生物手艺聚会。来自欧洲各地生命科学行业的资深专家将参会分享瑞士生物手艺乐成案例，并设有专题小组举行讨论！
The Swiss Biotech Day is the leading biotechnology conferences in Switzerland.
? Meet senior experts from the life science industry from across Europe.
? Swiss Biotech Success Stories.
? Innovative biotech start-ups and medium-sized biotech companies.
? Thematically focused panel discussions.
时间 (Date): May 2-3, 2022
所在 (Location): Basel, Switzerland
展位 (Booth): #13
尊龙凯时国际研发效劳部执行副总裁戴学东博士及英国和欧洲营业生长副总裁 Nadine Su女士将展示尊龙凯时一站式
药物发明效劳，并带来精彩演讲：PROTACs: Make Undruggable Targets Druggable。期待更多尊龙凯时 一站式药物发明效劳。演讲时间为：May 3, 13:00-13:15 (GMT+2)。
Medicilon VP of UK and Europe Business Development Ms. Nadine Su in person and Medicilon Executive VP and Head of IDSU, Dr. Xuedong Dai online, are invited to give a presentation to introduce Medicilon fully integrated drug discovery platform and focus on the topic of “PROTACs: Make Undruggable Targets Druggable”.
About Presenter
讲者信息
Dr. Xuedong Dai
Executive VP and Head of IDSU (International Discovery Service Unit) at Medicilon, obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expert with over 20 years of experience focusing on small molecule drug discovery and development in CNS, infectious disease, and oncology therapy areas. He has deep understanding and practical knowledge of drug discovery process, including lead identification, optimization, and development of high quality clinical candidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HD Biosciences, GSK, and Xenoport with a demonstrated successful track record of program leadership and made significant contributions to medicinal chemistry programs that led to the marketed drug Horizant?/Regnite? and several other clinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).
Ms. Nadine Su
20 years’ experience of project management and business development in pharmaceutical and healthcare industries include different sectors, include novel drug research and development, biotechnology application research project management, licensing and new business development in pharmaceutical and healthcare industry in Europe and China. She successfully developed and established the research partnership and business collaboration between EU and China for different novel drug research, novel biotechnology collaboration to achieve over $20M of licensing projects in a year.
Medicilon International Discovery Service Unit
尊龙凯时国际研发效劳部
尊龙凯时国际研发效劳部是尊龙凯时一站式生物医药临床前研发效劳平台的主要组成部分，使命是一连助力药企的国际化，向全球药物研发客户提供高质高效高性价比的合成化学、药物设计、以及新药候选化合物效劳，以知足客户在临床前新药研究的各个化学领域的研发需求，缩短药物研发的周期，降低药物研发的本钱。
尊龙凯时国际研发效劳部拥有富厚外洋留学事情配景的治理团队和实验职员、天下先进水平的合成实验室、剖析实验室、和配套的高端仪器装备。为了给客户提供更优质的效劳，国际研发效劳部紧跟药物设计以及合成的新希望和新手艺，如人工智能/机械学习（AI/ML），卵白降解靶向嵌合体（PROTAC），高活性药物及抗体药物偶联物（ADC），惰性碳氢键直接官能团化，光致氧化还原反应，以及流动化学等。
The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies. We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.
Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment. In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.
Medicilon PROTAC Platform
PROTAC手艺平台
尊龙凯时
PROTAC药物发明手艺平台汇总了目今盛行的热门的靶标卵白配体 ；建设了普遍的热门靶向卵白高度亲和力小分子及小分子片断化合物库（TPSM），普遍的E3毗连酶，高度亲和力的小分子及小分子片断（E3SM） ；建设了linker系统,包括网络大宗具有普遍多样性的双官能团毗连体（BF-Linker）。这些积累的化合物库可以资助快速高效的合成大宗高活性PROTAC双特异性小分子，极大地提高接纳PROTAC手艺举行的药物研发历程。除了快速合成之外，我们同时建设和完善的PROTAC生物筛选与测试平台，后续生长光临床前所有阶段。
Medicilon’s PROTAC drug discovery technology platform covers the currently popular target protein ligands. Medicilon has established a linker system with an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, Medicilon can efficiently synthesize a substantial amount of highly active PROTAC bispecific small molecules, which would have the potential to significantly facilitate ithe drug discovery and development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages.
联系尊龙凯时：
电话: +86 (21) 5859-1500（总机）
